Biotech manufacturing isn’t plug-and-play. Systems need to reflect the unique physical, regulatory, and operational demands of each process. “Deep technical knowledge allows the OEM partner to understand the critical nuances needed to design equipment for complex processes,” Todd explains. “This is especially true in areas like stem cell culture or engineered proteins.”

These processes require highly sensitive control systems, precise environmental parameters, and compatibility with rapidly evolving materials and technologies. Without biotech-specific expertise, an OEM risks delivering solutions that introduce friction, fail audits, or require extensive redesigns to work effectively.

Clients often turn to AES with questions about cGMP requirements, 21 CFR Part 11 compliance, and integrating components like Watson Marlow pumps or Raman spectrometers. Questions our team answers with real-world context drawn from previous builds.”. Todd’s team not only answers these questions but contextualizes them with examples from past builds, offering real-world validation without compromising client confidentiality. This level of detail and transparency builds trust and reveals technical depth.

I started in biotech right out of university, doing everything from operations to process sciences. What pulled me toward automation was the ability to really see how things worked. During a large capital project, I discovered I had a knack for automation. That insight, along with my early partnership with Leo, who shared a similar mindset, led me to AES. We both believe great automation engineers should be well-rounded—understanding process, equipment, and controls holistically.

When it comes to automation, many clients initially focus on hard metrics like time savings, yield improvements, and reduced labor costs. But as Chris and Matt explained, it’s often about targeting critical stages of the workflow where automation can do more than just save time but instead save entire batches.

Chris shared, “The biggest drivers we see are throughput and quality consistency. You might be trying to speed up the process, but more often, clients come to us because they’re dealing with failures, missed specs, product waste, or operator variability. Automation gives you the tools to eliminate that inconsistency.”

Matt echoed the importance of error reduction, especially where data is involved. “Manual processes are prone to mistakes, especially in documentation. Automating data capture through MES systems like Syncade, for example, cuts down on human error and ensures everything is logged in real-time, reducing compliance risk.”

While labour reduction is sometimes part of the discussion, both emphasized that it’s more about redistributing operator time to higher-value activities, such as oversight and troubleshooting.

It depends on the level of customization. For standard, off-the-shelf equipment, the baseline expectation is compliance with Good Manufacturing Practice (GMP) standards. This includes a comprehensive documentation package with design documents, operating manuals, and qualification protocols. Specific regulatory requirements, such as data integrity, audit trails, and compliance with 21 CFR Part 11 or EU Annex 11, must also be clearly addressed.

For partially or fully customized equipment, expectations are higher. End users look for a risk-based design approach aligned with GAMP 5 principles, full traceability from user requirements to testing protocols, and an integrated quality risk management process. OEMs must justify their design decisions, evaluate potential failure modes, and proactively collaborate with validation and quality teams. Full-service qualification covering DQ, IQ, OQ, and PQ support is often expected to streamline implementation.

In biotechnology operations—where precision, compliance, and system uptime are critical—AES provides comprehensive maintenance and service programs to ensure your equipment consistently delivers optimal performance. Our support extends asset life, minimizes downtime, and safeguards process integrity from R&D through to production.

Consider a mid-size bioproduction facility working on late-stage clinical material. When a valve unexpectedly failed, they didn’t have an emergency response contract or the part in stock. The result? A total batch loss and a five-week delay on a critical trial. “That kind of impact goes far beyond repair costs,” says Emily. “It affects timelines, team morale, even investor confidence.”

In highly regulated environments, delays can trigger a domino effect, pushing back validations, disrupting supply chains, and impacting patient access. With each hour of downtime, opportunity costs grow.

“One of the hardest placements we’re seeing right now is MES Syncade,” says Rebecca. “It’s a very specific system, and unless you’ve worked with it recently, candidates tend to hesitate. The learning curve and regulatory pressure make it a high-stakes environment.”

This challenge extends beyond skill matching. As Rosie notes, “Even if someone is a great technical fit, we often see last-minute drop-offs—people pulling out because of relocation or taking another offer. The unpredictability is significant.”

These variables—limited talent pools, system specificity, and candidate hesitancy—create a narrow window for successful hiring. And in biopharma environments where every week of delay can impact timelines, that window matters.